Kymera Therapeutics, Inc.
KYMR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$82,175 | -$76,614 | -$65,581 | -$70,752 |
| Dep. & Amort. | $2,149 | $2,084 | $2,048 | $1,987 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $15,802 | $15,416 | $14,233 | $13,799 |
| Change in WC | $38,478 | $1,351 | -$27,325 | $3,402 |
| Other Non-Cash | -$1,364 | -$2,121 | -$2,525 | -$10,220 |
| Operating Cash Flow | -$27,110 | -$59,884 | -$79,150 | -$61,784 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$181 | -$695 | -$467 | -$936 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | $0 | -$58,251 | -$83,656 | $0 |
| Inv. Sales/Matur. | $0 | $116,846 | $130,213 | $0 |
| Other Inv. Act. | -$235,118 | $2,121 | $2,525 | $69,504 |
| Investing Cash Flow | -$235,299 | $60,021 | $48,615 | $68,568 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$419 | -$382 | -$277 | -$293 |
| Stock Issued | $0 | $246,108 | $535 | $0 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $39,929 | $0 | $0 | $3,058 |
| Financing Cash Flow | $39,510 | $245,726 | $258 | $2,765 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | -$222,899 | $245,863 | -$30,277 | $9,549 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $341,636 | $95,773 | $126,050 | $116,501 |
| End Cash | $118,737 | $341,636 | $95,773 | $126,050 |
| Free Cash Flow | -$27,291 | -$60,579 | -$79,617 | -$62,720 |